Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSKJ1X)

• Drug Name: 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 9859248
  TTD Drug ID: DMSKJ1X

Molecule-Related Drug Atlas

Drug(s) Targeting G1/S-specific cyclin-E1 (CCNE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PD-0183812	DMWYP86	Retinoblastoma	2D02.2	Terminated	[2]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[3]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[3]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[3]
BMS-536924	DMXJB4N	Discovery agent	N.A.	Investigative	[4]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[3]
aloisine A	DM5U1LN	Discovery agent	N.A.	Investigative	[5]
3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol	DMJZK40	Discovery agent	N.A.	Investigative	[1]
(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime	DMGXRSZ	Discovery agent	N.A.	Investigative	[6]
(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime	DMZ0V6G	Discovery agent	N.A.	Investigative	[6]

Drug(s) Targeting G1/S-specific cyclin-D1 (CCND1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABT-263	DMNE56X	Myelofibrosis	2A20.2	Phase 3	[7]
Briciclib	DMK7BND	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[3]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[3]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[3]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[3]
7-hydroxycoumarin	DMTMNO7	Discovery agent	N.A.	Investigative	[9]

Drug(s) Targeting PRKACA messenger RNA (PRKACA mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VFEDEOUBYBLDKN-AAFJCEBUSA-N	DMH9ION	N. A.	N. A.	Patented	[10]
XHPNYYOUZWOWNT-PYUWXLGESA-N	DM5Q93Y	N. A.	N. A.	Patented	[10]
AGGGWZCOULSEER-PYUWXLGESA-N	DM2L83Y	N. A.	N. A.	Patented	[10]
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[11]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[12]
NM-PP1	DMS8H5Q	Discovery agent	N.A.	Investigative	[13]
ISIS 102633	DMWT7BK	Discovery agent	N.A.	Investigative	[14]
ISIS 102604	DMZ6X9B	Discovery agent	N.A.	Investigative	[14]
ISIS 102619	DMXH9IT	Discovery agent	N.A.	Investigative	[14]
ISIS 102462	DMXNC0B	Discovery agent	N.A.	Investigative	[14]

Drug(s) Targeting Cyclin-dependent kinase 9 (CDK9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flavopiridol	DMKSUOI	Acute myeloid leukaemia	2A60	Phase 2	[7]
P276-00	DM9DJL2	Mantle cell lymphoma	2A85.5	Phase 2	[15]
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[16]
SNS-032	DMEITAS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[17]
BTX-A51	DMC8XHQ	Advanced solid tumour	2A00-2F9Z	Phase 1	[18]
CYC065	DM9ODT6	Lymphoma	2A80-2A86	Phase 1	[7]
AZD4573	DMOYPTK	Haematological malignancy	2B33.Y	Phase 1	[7]
TP-1287	DM3Z07E	Solid tumour/cancer	2A00-2F9Z	Phase 1	[19]
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[20]
Roscovitine derivative 1	DMD1G3Z	N. A.	N. A.	Patented	[20]

Drug(s) Targeting Casein kinase II alpha (CSNK2A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CX-4945	DMWE7B9	Coronavirus infection	1D92	Phase 2	[7]
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[21]
EMODIN	DMAEDQG	N. A.	N. A.	Terminated	[22]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[22]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[22]
Apigenin	DMI3491	Discovery agent	N.A.	Investigative	[22]
PMID24900749C1a	DMZPUSO	Discovery agent	N.A.	Investigative	[23]
AdoC(Dpr)2AlaArg6	DM2TWSZ	Discovery agent	N.A.	Investigative	[24]
PMID22115617C2c	DMX5UKA	Discovery agent	N.A.	Investigative	[25]
5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole	DM3JB6S	Discovery agent	N.A.	Investigative	[22]

Drug(s) Targeting Cyclin A2 (CCNA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PD-0183812	DMWYP86	Retinoblastoma	2D02.2	Terminated	[2]
aloisine A	DM5U1LN	Discovery agent	N.A.	Investigative	[5]
3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol	DMJZK40	Discovery agent	N.A.	Investigative	[1]
MERIOLIN 8	DM0E95B	Discovery agent	N.A.	Investigative	[26]
2,5-dichloro-N-p-tolylthiophene-3-sulfonamide	DMU5J8Y	Discovery agent	N.A.	Investigative	[27]
Purvalanol A	DMNQ7TM	Discovery agent	N.A.	Investigative	[13]
MERIOLIN 1	DMJT93H	Discovery agent	N.A.	Investigative	[26]
MERIOLIN 4	DMIJMZQ	Discovery agent	N.A.	Investigative	[26]
MERIOLIN 6	DMW5AXC	Discovery agent	N.A.	Investigative	[26]
MERIOLIN 5	DMGVLR0	Discovery agent	N.A.	Investigative	[26]

Drug(s) Targeting Extracellular signal-regulated kinase 2 (ERK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BVD-523	DMNB4XK	Melanoma	2C30	Phase 2	[28]
HH2710	DM0C5MV	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[29]
ASTX029	DMVZXIA	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[30]
VAN-10-4-eluting stent	DM3ZW6A	Artery stenosis	BD52	Phase 1	[31]
GDC-0994	DMFC2OY	Solid tumour/cancer	2A00-2F9Z	Phase 1	[32]
JSI-1187	DMVJWBS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[33]
LY3214996	DMFDAY7	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
CHIR-99021	DMB8MNU	Allergic inflammation	4A80-4A85	Patented	[34]
COR-D	DMLXMCB	T-cell leukaemia	2A90	Preclinical	[35]
SB220025	DMSBUET	Arthritis	FA20	Terminated	[36]

Drug(s) Targeting Checkpoint kinase-1 (CHK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY2603618	DMCXRZF	Pancreatic cancer	2C10	Phase 2	[37]
UCN-01	DMUNJZB	Non-small-cell lung cancer	2C25.Y	Phase 2	[38]
SCH-900776	DM67EMK	Solid tumour/cancer	2A00-2F9Z	Phase 2	[39]
LY2606368	DM4XMF7	Ovarian cancer	2C73	Phase 2	[7]
LY2880070	DMADEHZ	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[40]
RG7741	DMK6P9J	Lymphoma	2A80-2A86	Phase 1	[41]
GDC-0425	DMDZ26X	Lymphoma	2A80-2A86	Phase 1	[42]
AZD7762	DM1FW0C	Solid tumour/cancer	2A00-2F9Z	Phase 1	[43]
MK-8776	DMAS1RB	Hodgkin lymphoma	2B30	Phase 1	[44]
Diamidothiazole derivative 1	DM02V5Q	N. A.	N. A.	Patented	[20]

Drug(s) Targeting Tyrosine-protein kinase ABL1 (ABL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[45]
Bosutinib	DMTI8YE	Breast cancer	2C60-2C65	Approved	[46]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[47]
Adenosine triphosphate	DM79F6G	Malnutrition	5B50-5B71	Approved	[48]
Saracatinib	DMBLHGP	Hematologic tumour	2B33.Y	Phase 2	[49]
Flumatinib	DM0G5O6	Chronic myelogenous leukaemia	2A20.0	Phase 2	[50]
DCC-2036	DMJKFNU	Chronic myeloid leukaemia	2A20	Phase 1/2	[51]
ISIS-CRP	DMQDUG4	Cardiovascular disease	BA00-BE2Z	Phase 1	[52]
KW-2449	DMFO7RP	Acute myeloid leukaemia	2A60	Phase 1	[53]
PMID27774824-Compound-Figure9Example2down	DMXAV42	N. A.	N. A.	Patented	[54]

Drug(s) Targeting Stress-activated protein kinase 2a (p38 alpha)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ozagrel	DMIGKA1	Xerophthalmia	5B55.Y	Phase 4	[55]
Losmapimod	DMIL37Z	Acute coronary syndrome	BA41	Phase 3	[55]
VX-702	DMKJDR6	Coronary artery disease	BA80	Phase 2a	[56]
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[57]
Dilmapimod	DMBYJ92	Acute lung injury	NB32.3	Phase 2	[55]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[58]
PMID25991433-Compound-F2	DM37VIQ	N. A.	N. A.	Patented	[58]
PMID25991433-Compound-L2	DM58UO9	N. A.	N. A.	Patented	[58]
PMID25991433-Compound-L3	DM3LWUR	N. A.	N. A.	Patented	[58]
PMID25991433-Compound-L1	DM2135Y	N. A.	N. A.	Patented	[58]

Drug(s) Targeting RAC-alpha serine/threonine-protein kinase (AKT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enzastaurin	DM5H0R9	Diffuse large B-cell lymphoma	2A81	Phase 3	[7]
AZD5363	DM9SKW8	Triple negative breast cancer	2C60-2C65	Phase 3	[7]
GDC-0068	DMWBZJD	Breast cancer	2C60-2C65	Phase 3	[7]
CI-1033	DMSI8N3	Lymphoma	2A80-2A86	Phase 2	[46]
CMX-2043	DMPSCVY	Cardiac disease	BA00-BE2Z	Phase 2	[59]
ARQ 092	DM5WK0J	Proteus syndrome	LD2C	Phase 2	[60]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[61]
RX-0201	DMTBAV3	Pancreatic cancer	2C10	Phase 2	[62]
Trametinib + 2141795	DMYP7TO	Solid tumour/cancer	2A00-2F9Z	Phase 2	[61]
PTX-200	DM0ZIT2	Breast cancer	2C60-2C65	Phase 2	[7]

Drug(s) Targeting Cyclin-dependent kinase 2 (CDK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[15]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[46]
PHA848125	DMS2Q9G	Thymic cancer	2C27	Phase 2	[63]
TG02	DMZFIGQ	Anaplastic astrocytoma	2A00.0	Phase 1/2	[64]
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[16]
FN-1501	DM7BMD6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[65]
AG-024322	DMY4WVK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
PHA-793887	DM2Y4FG	Solid tumour/cancer	2A00-2F9Z	Phase 1	[66]
SNS-032	DMEITAS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[17]
CYC065	DM9ODT6	Lymphoma	2A80-2A86	Phase 1	[7]

Drug(s) Targeting Glycogen synthase kinase-3 beta (GSK-3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMO-02	DMJRU3A	Myotonic dystrophy	8C71.0	Phase 2/3	[67]
LY2090314	DMTBFE4	Acute myeloid leukaemia	2A60	Phase 2	[68]
Lithium	DMZ3OU6	Fragile X syndrome	LD55	Phase 2	[69]
Tideglusib	DME4LA1	Osteosarcoma	2B51	Phase 2	[70]
9-ING-41	DM57TY3	Myelofibrosis	2A20.2	Phase 2	[71]
Neu-120	DMXKOUC	Parkinson disease	8A00.0	Phase 1/2	[72]
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[73]
CHIR-99021	DMB8MNU	Allergic inflammation	4A80-4A85	Patented	[34]
TDZD-8	DMG6Q45	Malignant glioma	2A00.0	Patented	[74]
AR-A014418	DMUPN01	Ovarian cancer	2C73	Patented	[75]

Drug(s) Targeting cAMP protein kinase type II-beta (PRKAR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[11]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[12]
[3H]cAMP	DMZRQU7	Discovery agent	N.A.	Investigative	[36]
AdoC(Dpr)2AlaArg6	DM2TWSZ	Discovery agent	N.A.	Investigative	[24]
AdcAhxArg4NH(CH2)6NH2	DMSYMRJ	Discovery agent	N.A.	Investigative	[76]
AdcAhxArg4Lys-PEGOMe	DMQ2C8X	Discovery agent	N.A.	Investigative	[76]
AdoC(GABA)Arg6	DMMWNPT	Discovery agent	N.A.	Investigative	[24]
AdcAhxArg4Lys(biotin)-PEG-OMe	DMZYJHV	Discovery agent	N.A.	Investigative	[76]
AdoC(Aun)Arg6	DMDLHAB	Discovery agent	N.A.	Investigative	[24]
AdoCGlyArg6	DMVQJP0	Discovery agent	N.A.	Investigative	[24]

Drug(s) Targeting Cyclin-dependent kinase 4 (CDK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apremilast	DMTWS9E	Psoriasis vulgaris	EA90	Approved	[77]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[78]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[79]
Ribociclib succinate	DM9CIUW	Breast cancer	2C60-2C65	Approved	[80]
Trilaciclib	DMP5A4T	Small-cell lung cancer	2C25.Y	Approved	[81]
LEE011	DMMX75K	Breast cancer	2C60-2C65	Phase 3	[82]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[46]
P276-00	DM9DJL2	Mantle cell lymphoma	2A85.5	Phase 2	[15]
P-276	DMMJUHD	Breast cancer	2C60-2C65	Phase 2	[83]
G1T38	DMQO2IT	Breast cancer	2C60-2C65	Phase 2	[7]

Drug(s) Targeting Fungal Protein kinase A (Fung ypkA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[11]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[12]
PMID20005102C1	DMMESBW	Discovery agent	N.A.	Investigative	[84]
[3H]cAMP	DMZRQU7	Discovery agent	N.A.	Investigative	[85]
PMID19364658C33	DMSE1C3	Discovery agent	N.A.	Investigative	[86]
BX-912	DMZA45C	Discovery agent	N.A.	Investigative	[87]
BX-795	DMRIMLJ	Discovery agent	N.A.	Investigative	[87]
Chelerythrine	DMCP1G9	Discovery agent	N.A.	Investigative	[88]
PMID21742770C1	DME3JMH	Discovery agent	N.A.	Investigative	[89]
Rp-adenosine 3',5'-cyclic monophosphothioate triethylamine (Rp-cAMPS)	DM1JWGH	Discovery agent	N.A.	Investigative	[90]

Drug(s) Targeting Ribosomal protein S6 kinase beta-1 (S6K1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
M2698	DM3PVBJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
PF-4708671	DMO0892	Ulcerative colitis	DD71	Clinical trial	[91]
PMID27410995-Compound-Figure3c	DMDQMZT	N. A.	N. A.	Patented	[92]
Pyrimido[4,5-d] pyrimidines and pyrido[4,3-d] pyrimidine derivative 1	DM6O2Q9	N. A.	N. A.	Patented	[92]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[93]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[94]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[93]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[93]
Ro31-8220	DMDJLF0	Discovery agent	N.A.	Investigative	[93]
STAUROSPORINONE	DMU2H4K	Discovery agent	N.A.	Investigative	[93]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
cAMP protein kinase type II-beta (PRKAR2B)	TTW4Y2M	KAP3_HUMAN	Inhibitor	[1]
Casein kinase II alpha (CSNK2A1)	TTER6YH	CSK21_HUMAN	Inhibitor	[1]
Checkpoint kinase-1 (CHK1)	TTTU902	CHK1_HUMAN	Inhibitor	[1]
Cyclin A2 (CCNA2)	TTAMQ62	CCNA2_HUMAN	Inhibitor	[1]
Cyclin-dependent kinase 2 (CDK2)	TT7HF4W	CDK2_HUMAN	Inhibitor	[1]
Cyclin-dependent kinase 4 (CDK4)	TT0PG8F	CDK4_HUMAN	Inhibitor	[1]
Cyclin-dependent kinase 9 (CDK9)	TT1LVF2	CDK9_HUMAN	Inhibitor	[1]
Extracellular signal-regulated kinase 2 (ERK2)	TT4TQBX	MK01_HUMAN	Inhibitor	[1]
Fungal Protein kinase A (Fung ypkA)	TTYVI76	Q56921_YEREN	Inhibitor	[1]
G1/S-specific cyclin-D1 (CCND1)	TTFCJ7S	CCND1_HUMAN	Inhibitor	[1]
G1/S-specific cyclin-E1 (CCNE1)	TTCEJ4F	CCNE1_HUMAN	Inhibitor	[1]
Glycogen synthase kinase-3 beta (GSK-3B)	TTRSMW9	GSK3B_HUMAN	Inhibitor	[1]
PRKACA messenger RNA (PRKACA mRNA)	TT5U49F	KAPCA_HUMAN	Inhibitor	[1]
RAC-alpha serine/threonine-protein kinase (AKT1)	TTWTSCV	AKT1_HUMAN	Inhibitor	[1]
Ribosomal protein S6 kinase beta-1 (S6K1)	TTG0U4H	KS6B1_HUMAN	Inhibitor	[1]
Stress-activated protein kinase 2a (p38 alpha)	TTQBR95	MK14_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase ABL1 (ABL)	TT3PJMV	ABL1_HUMAN	Inhibitor	[1]

References

• [1] 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
• [2] Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
• [3] Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
• [4] Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
• [5] Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
• [6] 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Clinical pipeline report, company report or official report of Onconova.
• [9] Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin. Lung Cancer. 2001 Nov;34(2):185-94.
• [10] Purine derivatives. US8846696.
• [11] Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry. J Med Chem. 2005 Sep 8;48(18):5613-38. Address
• [12] Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
• [13] The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
• [14] US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
• [15] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [16] Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
• [17] Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
• [18] Clinical pipeline report, company report or official report of BioTheryX.
• [19] Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
• [20] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [21] Synthesis and protein kinase C inhibitory activities of acyclic balanol analogs that are highly selective for protein kinase C over protein kinase A. J Med Chem. 1996 Dec 20;39(26):5215-27.
• [22] Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3.
• [23] Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. ACS Med Chem Lett. 2013 Jul 3;4(8):800-5.
• [24] Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
• [25] CK2alpha and CK2alpha' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives. Eur J Med Chem. 2012 Jan;47(1):345-50.
• [26] Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
• [27] Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010).
• [28] DOI: 10.1158/1538-7445.AM2015-4693
• [29] Clinical pipeline report, company report or official report of HaiHe Biopharma.
• [30] Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
• [31] WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
• [32] ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
• [33] National Cancer Institute Drug Dictionary (drug name JSI1187).
• [34] Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
• [35] Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
• [36] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [37] Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26.
• [38] Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening app... J Mol Graph Model. 2009 Sep;28(2):113-30.
• [39] Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
• [40] A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3581-3581.
• [41] National Cancer Institute Drug Dictionary (drug id 730054).
• [42] Quantitative assessment of BCL-2:BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199).
• [43] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [44] Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. Int J Mol Sci. 2019 Aug 22;20(17):4095.
• [45] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [46] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [47] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [48] Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15.
• [49] Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
• [50] Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2014 Jan;105(1):117-25.
• [51] Company report (Deciphera Pharmaceuticals: Tumor-Targeted Programs and Indications)
• [52] Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J Med Chem. 2008 Mar 13;51(5):1252-9.
• [53] KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17.
• [54] Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
• [55] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [56] Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
• [57] Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
• [58] c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
• [59] Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64.
• [60] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [61] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
• [62] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [63] Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.
• [64] Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
• [65] Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
• [66] A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
• [67] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [68] Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
• [69] The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
• [70] Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904.
• [71] 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977.
• [72] Company report (Neurim Pharmaceuticals)
• [73] 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
• [74] Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6.
• [75] Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
• [76] Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9.
• [77] Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
• [78] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [79] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
• [80] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [81] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [82] Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
• [83] Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
• [84] 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
• [85] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1694).
• [86] Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51.
• [87] Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
• [88] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
• [89] A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038.
• [90] Inhibition of protein kinase A activity interferes with long-term, but not short-term, memory of conditioned taste aversions. Behav Neurosci. 2002 Dec;116(6):1070-4.
• [91] Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J. 2010 Oct 15;431(2):245-55.
• [92] Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
• [93] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [94] Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.